Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome
The study aims to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS).
Polycystic Ovary Syndrome (PCOS)
DRUG: Empagliflozin 25 mg|DRUG: Linagliptin 10 mg|DRUG: Metformin 1500 mg
Fertility parameters, \[luteinizing hormone (LH), 3-6 months|Follicle-stimulating hormone, FSH, 3-6 months|Free androgen index, total testosterone \& sex hormone binding globulin (SHBG), 3-6 months|Transvaginal ultrasonography, disappearance of PCOS, 3-6 months|Menstrual diaries, regulate menses cycles, 3-6 months
Metabolic parameters, Fasting blood glucose level, 3-6 months|Lipid profile (metabolic parameters), Total cholesterol, Low density lipoprotein (LDL), very low density lipoprotein (VLDL), high density lipoprotein (HDL), triglycerides (TG), atherogenic index I, II, 3-6 months|Inflammatory indices, Interleukin 6 or Toll Like receptor 2, 3-6 months
Patients with polycystic ovary syndrome will be randomized to three arms:

* Metformin (standard care)
* Empagliflozin or Linagliptin Resolution of the syndrome in addition to normalization of sex hormones, metabolic and inflammatory parameters will be tested